The UK government will move ahead with plans to restrict the use of drugs to treat Alzheimer's disease to patients with moderate symptoms, according to the National Institute of Health and Clinical Excellence (NICE).
In a statement, NICE chief executive Andrew Dillon said: "we realise that today's announcement will be disappointing to people with Alzheimer's and those who treat and care for them. But we have to be honest and say that based on all the evidence, including data presented by the drug companies themselves, our experts have concluded that these drugs do not make enough of a difference for us to recommend their use for treating all stages of Alzheimer's disease."The ruling, due to come into effect in November, affects the cholinesterase inhibitors on the UK market, namely Eisai/Pfizer's Aricept (donepezil), Shire's Reminyl (galantamine) and Novartis' Exelon (rivastigmine).
2 comments:
Medivation is a company that the Cargo Cult Scientist has put in its sites. They have a nearly zero percent chance at a drug approval. If they succeed it will be due to the failure of the FDA to distinguish shit from shinola. Stay tuned for how this one ends.
Their drug is a cholinesterase inhibitor.
Post a Comment